Institution
Emory University
Education•Atlanta, Georgia, United States•
About: Emory University is a education organization based out in Atlanta, Georgia, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 51959 authors who have published 122469 publications receiving 6010698 citations.
Topics: Population, Poison control, Transplantation, Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: To address the health challenges and maximise the benefits that accompany this rapid urbanisation, innovative health policies focused on the needs of migrants and research that could close knowledge gaps on urban population exposures are needed.
930 citations
••
TL;DR: Although CTCF has been assigned various roles that are often contradictory, new results now help to draw a unifying model to explain the many functions of this protein.
Abstract: CCCTC-binding factor (CTCF) is a DNA-binding protein that has various, often seemingly contradictory, roles in gene regulation. This Review describes these disparate functions and how the context-dependent looping of DNA regions by CTCF is emerging as a potential unifying mechanism that underpins these diverse roles.
930 citations
••
Emory University1, University of Mississippi2, University of Texas Southwestern Medical Center3, University of California, San Francisco4, The Royal Marsden NHS Foundation Trust5, University of Washington6, University of Iowa Hospitals and Clinics7, St. Joseph's Hospital and Medical Center8, Memorial Hospital of Rhode Island9, University of Michigan10, Western Pennsylvania Hospital11, NorthShore University HealthSystem12, Duke University13, University of Pennsylvania14, University of British Columbia15, Merck & Co.16
TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.
Abstract: A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.
928 citations
••
Penn State Milton S. Hershey Medical Center1, Kaiser Permanente2, Northwestern University3, University of Cincinnati4, NewYork–Presbyterian Hospital5, Cornell University6, Boston University7, University of Alabama at Birmingham8, Johns Hopkins University9, University of Miami10, University of Pennsylvania11, Harvard University12, Mount Sinai Health System13, Henry Ford Health System14, Mayo Clinic15, Emory University16, Swedish Covenant Hospital17, American Academy of Dermatology18
TL;DR: Issues from grading of acne to the topical and systemic management of the disease are reviewed and suggestions on use are provided based on available evidence.
Abstract: Acne is one of the most common disorders treated by dermatologists and other health care providers. While it most often affects adolescents, it is not uncommon in adults and can also be seen in children. This evidence-based guideline addresses important clinical questions that arise in its management. Issues from grading of acne to the topical and systemic management of the disease are reviewed. Suggestions on use are provided based on available evidence.
928 citations
••
TL;DR: The third in the Child Development Series as discussed by the authors assesses strategies to promote child development and to prevent or ameliorate the loss of developmental potential in developing countries by identifying four well-documented risks: stunting, iodine deficiency, iron deficiency anaemia, and inadequate cognitive stimulation, plus four potential risks based on epidemiological evidence.
927 citations
Authors
Showing all 52622 results
Name | H-index | Papers | Citations |
---|---|---|---|
Younan Xia | 216 | 943 | 175757 |
Eric J. Topol | 193 | 1373 | 151025 |
Bernard Rosner | 190 | 1162 | 147661 |
Paul G. Richardson | 183 | 1533 | 155912 |
Peter W.F. Wilson | 181 | 680 | 139852 |
Dennis S. Charney | 179 | 802 | 122408 |
Joseph Biederman | 179 | 1012 | 117440 |
Kenneth C. Anderson | 178 | 1138 | 126072 |
David A. Weitz | 178 | 1038 | 114182 |
Lei Jiang | 170 | 2244 | 135205 |
William J. Sandborn | 162 | 1317 | 108564 |
Stephen J. Elledge | 162 | 406 | 112878 |
Ali H. Mokdad | 156 | 634 | 160599 |
Michael Tomasello | 155 | 797 | 93361 |
Don W. Cleveland | 152 | 444 | 84737 |